Skip to main content
. 2001 Jul;75(13):6228–6234. doi: 10.1128/JVI.75.13.6228-6234.2001

FIG. 4.

FIG. 4

FIG. 4

FIG. 4

BRLF1-CBP interaction affects BRLF1 transactivator function. (A) Transient reporter assays were performed in which HeLa cells were transfected with 4 μg of promoter construct (S-CAT, containing SM gene promoter sequences), 0.3 μg of BRLF1 expression vector (CMV-RIE) (26), or control vector (pHD1013), with or without 1 μg of the CMV-CBP expression vector (29). CAT activity was determined as previously described (20). The results represent data from two separate experiments. (B) The S-CAT plasmid (1 μg) was transfected into HeLa cells with either vector DNA (8.5 μg) (SG5), wild-type E1A vector (8 μg), an E1A mutant (Δ2-36) which is unable to bind CBP (8 μg), the BRLF1 expression vector (pRTS15; a gift from Diane Hayward) (0.5 μg) and control vector DNA (8 μg), the BRLF1 expression vector (0.5 μg) and wild-type E1A (8 μg), or the BRLF1 expression vector (0.5 μg) and the E1A mutant (Δ2-36) (8 μg). The E1A vectors were gifts from David Livingston (8). (C) Immunoblot analysis was performed using extracts from the experiment shown in panel 4B to assess the level of transfected wild-type versus mutant E1A proteins and of BRLF1.